Acceleron Pharma Inc. (XLRN) |
|
178.75 0 (0%)
|
12-31 19:00 |
|
Open: |
179.85 |
Pre. Close: |
178.75 |
|
High:
|
179.85 |
Low:
|
177.2 |
|
Volume:
|
7,884,284 |
Market Cap:
|
0(M) |
|
|
|
Technical analysis |
as of: 2022-01-21 4:31:52 PM |
|
Short-term rate:
|
 |
| Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
|
Mid-term rate:
|
 |
| Target: |
Six months: 210.06 One year: 245.35 |
| Support: |
Support1: 178.21 Support2: 177.19 |
| Resistance: |
Resistance1: 179.85 Resistance2: 210.06 |
| Pivot: |
178.75 |
| Moving Average: |
MA(5): 178.75 MA(20): 178.75
MA(100): 170.29 MA(250): 144.27 |
| MACD: |
MACD(12,26): 0.2  Signal(9): 0.28 |
| Stochastic oscillator: |
%K(14,3): 58.49 %D(3): 58.49 |
| RSI: |
RSI(14): 71.18 |
| 52-week: |
High: 189.99 Low: 111.75 |
| Average Vol(K): |
3-Month: 0 (K) 10-Days: 0 (K) |
|
Price, moving averages and Bollinger Bands |
|
|
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
- |
- |
|
Low:
|
- |
- |
|
Close:
|
- |
- |
|
Company Description |
|
Acceleron Pharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. It offers luspatercept-aamt for the treatment of anemia in adult patients with beta-thalassemia under the REBLOZYL name. The company also develops luspatercept-aamt for the treatment of myelodysplastic syndromes and myelofibrosis; Sotatercept for the treatment of patients with pulmonary arterial hypertension; and ACE-083, a neuromuscular candidate that is in Phase II clinical trials for the treatment of patients with Charcot-Marie-Tooth disease. In addition, it has a collaboration, license, and option agreement with Celgene Corporation; and collaboration and license agreement with Fulcrum Therapeutics, Inc. to identify small molecules designed to modulate specific pathways associated with a targeted indication within the pulmonary disease space. The company was formerly known as Phoenix Pharma, Inc. Acceleron Pharma Inc. was founded in 2003 and is headquartered in Cambridge, Massachusetts. |
Headline News |
Wed, 30 Aug 2023
New nod brings Reblozyl into first-line treatment setting - The Pharma Letter
Wed, 05 Jul 2023
Lehigh Names New Trustees - Lehigh University
Mon, 22 Nov 2021
Merck Closes Deal for Acceleron Pharma, Biggest Biotech Merger of the Year - Barron's
Mon, 22 Nov 2021
Merck Completes Acquisition of Acceleron Pharma Inc. - Business Wire
Tue, 09 Nov 2021
Avoro Capital Releases Presentation Detailing Why Acceleron ... - Business Wire
Thu, 04 Nov 2021
Acceleron Reports Third Quarter 2021 Financial Results - Business Wire
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
61 (M) |
| Shares Float |
50 (M) |
|
% Held by Insiders
|
11.7 (%) |
|
% Held by Institutions
|
91.4 (%) |
|
Shares Short
|
1,680 (K) |
|
Shares Short P.Month
|
1,980 (K) |
Stock Financials |
|
EPS
|
-3.72 |
|
EPS Est Next Qtl
|
-0.64 |
|
EPS Est This Year
|
-2.7 |
|
EPS Est Next Year
|
-2.28 |
|
Book Value (p.s.)
|
12.56 |
|
Profit Margin (%)
|
-221.14 |
|
Operating Margin (%)
|
-221.59 |
|
Return on Assets (ttm)
|
-21.3 |
|
Return on Equity (ttm)
|
-37.76 |
|
Qtrly Rev. Growth
|
-29.71 |
|
Gross Profit (p.s.)
|
-1.34 |
|
Sales Per Share
|
1.65 |
|
EBITDA (p.s.)
|
-3.61 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-193 (M) |
|
Levered Free Cash Flow
|
-108 (M) |
Stock Valuations |
|
PE Ratio
|
-48.19 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
14.23 |
|
Price to Sales
|
108.04 |
|
Price to Cash Flow
|
-0.01 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
